Your session is about to expire
← Back to Search
Camizestrant for Liver Disease
Study Summary
This trial tests a drug on post-menopausal women with normal, moderate or severe liver impairment to see how safe & effective it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I do not have any serious ongoing infections.I have tested positive for COVID-19 recently.You cannot stop or expect to use:I have a significant thyroid condition.I have a history of HIV or tested positive for hepatitis B or C.I have had liver problems for more than 6 months without getting worse recently.My liver functions normally and I have no significant health issues.I haven't taken HIV protease inhibitors or anticoagulants in the last 14 days.I am mentally capable and do not have significant emotional issues that would affect my participation.I have significant vision problems, including hallucinations or frequent dizziness.I don't have conditions that affect medicine absorption due to stomach surgery.I haven't taken any strong medication that affects liver enzymes or certain drug transporters in the last month.You have had problems with alcohol or drug abuse within the past two years.My kidneys are not working well (creatinine clearance < 60 mL/min).My diabetes is not well-controlled.I have been diagnosed with HIV.I haven't taken acetaminophen or ethacrynic acid in the last 24 hours.I have not donated more than 500 mL of blood or had significant blood loss in the last 56 days.I have not donated plasma in the last 28 days.I haven't taken any medication that affects heart rhythm in the last 4 weeks or longer.You have used drugs recreationally within the past 2 years before the screening.I am currently taking medication, whether prescribed or over-the-counter.Your resting heart rate is too low (less than 50 beats per minute) or too high (more than 99 beats per minute) when lying down.I agree not to use warfarin or phenytoin during and for 2 weeks after the study.You have a special tube called a transjugular intrahepatic portosystemic shunt in your body.You have had an allergic reaction to camizestrant or similar drugs in the past.My liver functions are normal, so I might not qualify.I do not have any major health or mental issues that would affect my participation.I have not had major surgery in the last 30 days.I do not have severe liver problems.My liver works normally and I am matched with someone of similar age who has liver issues.I am between 50 and 75 years old with liver problems.I have liver problems but am in good health otherwise.I weigh between 50 to 100 kg and my BMI is between 19.0 to 35.0.I am a woman who has not had a period for 12 months due to menopause.My liver works normally and my weight matches someone with liver issues within 20%.You are capable of providing written confirmation that you understand the requirements and restrictions outlined in the ICF and this protocol.
- Group 1: Group 1
- Group 2: Group 2
- Group 3: Group 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is my participation in this experiment permissible?
"This trial is recruiting 28 individuals with liver condition in the age range between 50 and 75. Notably, participants need to agree that they will not use warfarin or phenytoin (and similar vitamin K antagonist anticoagulants) from screening through 2 weeks after administration of study drug."
Does this research endeavor accept patients below the age of 50?
"This trial is including individuals aged between 50 and 75 years."
What risks do individuals face when undergoing this treatment?
"This treatment has been evaluated and given a score of 1 on the scale since it is currently in Phase 1, indicating that limited data exists to support its safety or efficacy."
How many participants are currently being recruited for this investigation?
"Indeed, the information on clinicaltrials.gov states that this trial is still enrolling participants. The initial posting of this study was made on February 20th2023 and it has been refreshed as recently as May 19th2023. As such, 28 individuals are being recruited across 3 different medical centres."
Is enrollment for this clinical trial open at present?
"The clinicaltrial.gov website shows that this research endeavor is actively seeking patients; first posted on February 20th, 2023 and last edited on May 19th, 2023."
Share this study with friends
Copy Link
Messenger